5 December 2022 in Histopathology
24 August 2020 in Molecular Carcinogenesis
Sal‐like protein 4 (SALL4) is overexpressed in breast cancer and might contribute to breast cancer progression, but the molecular mechanism remains unknown. Here, we found that within a group of 371 ethnic Chinese breast cancer patients, SALL4 was associated with lower grade (P = .002) and progesterone receptor positivity (P = .004) for overall cases; lower Ki67 (P = .045) and high vimentin (P = .007) for luminal cases. Patients with high SALL4 expression in lymph node metastasis showed a significantly worse survival than those with low expression. Knockout of SALL4 in a triple‐negative breast cancer cell line MDA‐MB‐231‐Red‐FLuc‐GFP led to suppressed ability in proliferation, clonogenic formation, migration, and mammosphere formation in vitro, tumorigenicity and lung colonization in vivo. On the other hand, overexpression of SALL4 enhanced migration and mammosphere formation in vitro and tumorigenicity in vivo. Mechanistically, there was a positive correlation between SALL4 expression and mesenchymal markers including Zinc finger E‐box binding homeobox 1 (ZEB1), vimentin, Slug, and Snail in vivo. Chromatin immunoprecipitation experiment indicated that SALL4 can bind to the promoter region of vimentin (−778 to −550 bp). Taken together, we hypothesize that SALL4 promotes tumor progression in breast cancer by inducing the mesenchymal markers like vimentin through directly binding to its promoter. Increased SALL4 level in metastatic lymph node relative to the primary site is an important poor survival marker in breast cancer.
31 October 2024 in Histopathology
Aims: This study evaluates the utility of breast specific markers in identifying breast cancer subtypes within metastatic settings. The subtype alteration in metastatic disease and its consequent impact on breast‐specific marker expression is also examined.Materials and methods: GATA‐binding protein 3 (GATA3), mammaglobin (MMG), transcriptional repressor GATA binding 1 (TRSP1) and SRY‐box transcription factor 10 (SOX10) expression were assessed in a large cohort of metastatic breast cancer (MBC) cases and correlated with the characteristics of both MBC and primary breast cancer (PBC).Results: GATA3 was the most sensitive in MBC (83.1%), followed by TRPS1 (77.0%), MMG (58.5%) and SOX10 (7.1%). This trend was consistent in hormonal receptor (HR)+ and HR− MBC. Combining GATA3/TRPS1 yielded the highest detection rates in the overall cohort (90.1%) and HR+ MBC (97.1%), while TRSP1/MMG was most effective in HR− (76.2%) and TN (71.1%) MBC. Marker expression did not correlate with metastatic site, except SOX10 in lung metastases (P = 0.031). Subtype discordance between MBC and PBC occurred in 43 cases (24.4%), with GATA3 expression in HR− MBC significantly linked to subtype discordance (P = 0.005). Conversely, SOX10 expression was significantly associated with subtype concordance in HR− and TNBC (P ≤ 0.003). Despite a higher expression of GATA3 in all HR− cases, TRSP1 outperformed GATA3 in detecting concordant HR− cases (64.0% versus 38.5%). TRPS1 and SOX10 were expressed in more than 50% of concordant TNBC cases.Conclusions: The expression of breast‐specific markers is mainly determined by the PBC subtype. GATA3 retains high sensitivity in HR+ cancers, even after HR loss during metastasis. TRPS1 and SOX10 are identified as valuable markers in TNBC metastasis.
23 April 2025 in IEEE Transactions on Image Processing
Tumor-stroma ratio (TSR), which is the area ratio between two components within tumor beds, namely tumor cells and tumor stroma, has been suggested as a promising prognostic feature in breast cancers. However, due to imperfect datasets, and the similarity between tumor stroma and non-tumor stroma, previous algorithms struggle to delineate tumor beds, especially those of histomorphologies with a fibrotic focus. To overcome these limitations, we propose a novel ray-aided quadruple affiliation network (RQA-Net) for calculating TSRs in breast cancers. RQA-Net uses quadruple branches to segment tumor cells and tumor beds simultaneously, where a crisscross task subtraction module (CTS-Module) is designed to locate tumor stroma, grounded on its affiliation relationships with tumor beds. Moreover, we propose an affiliation loss (Aff-Loss) to force identified tumor beds to incorporate tumor cells to enhance their affiliation relationships. Furthermore, we propose a ray-based hypothesis testing (RH-Testing) to obtain line segments from ray equations in tumor beds that can decorate identified tumor beds by overlapping. In summary, RQA-Net precisely predicts tumor cells and tumor beds, and thus supports the calculation of TSRs. We also create a cancerous dataset (CrD-Set) containing 100 slides with an average resolution of 50,000 × 50,000 pixels from real breast cancer cases, which is the first dataset with pixel-wise tumor bed annotations. Experimental results on existing datasets and CrD-Set demonstrate that compared with previous methods, RQA-Net better calculates breast cancer TSRs by precisely identifying tumor cells and tumor beds. The created CrD-Set and codes in this work will be available online at https://github.com/Kunpingyang1992/Breast-Cancer-TSR-Calculation.
29 March 2026 in Histopathology
Aims: De‐escalated treatment for ductal carcinoma in situ (DCIS) aims to prevent overtreatment of patients. However, patients diagnosed preoperatively with pure DCIS via core needle biopsy (CNB) may be upgraded to invasive cancer upon excision. Therefore, it is essential to stratify patients at low risk for upgrade to invasive disease during the biopsy to inform management decisions. Methods and results: In this study, we reviewed a cohort of patients with pure DCIS diagnosed by CNB and their corresponding excision specimens to identify predictive features for upgrading to microinvasion or invasive breast cancer (IBC). Of the 228 CNB cases, 82 (36%) were upgraded at excision, with 26.8% classified as microinvasion and 73.2% as frank invasion. Significant tumour intrinsic features associated with DCIS upgrade included larger tumour size, palpable mass, high grade and presence of necrosis ( P ≤ 0.026). Factors related to sampling adequacy, such as the number of cores, total core length and length of the longest core, were also predictive features ( P ≤ 0.027). Additionally, tumour microenvironment (TME) characteristics, including calcification and stromal tumour‐infiltrating lymphocytes (sTIL), were linked to upgrades, particularly in the human epidermal growth factor 2 (HER2)‐negative subgroup ( P ≤ 0.004). These features were independently associated with frank invasion in HER2‐negative cancers. Conclusions: Our results provide valuable insights into additional predictive features for DCIS upgrade. When combined with adequate sampling and intrinsic tumour characteristics, TME features—namely tumour infiltrating lymphocytes (TILs) and calcification—are useful in predicting DCIS upgrades, especially in HER2‐negative cases.
9 October 2026 in Histopathology
Introduction: The presence of non‐progressing ductal carcinoma in situ (DCIS) cases has raised concerns of overtreatment, necessitating comprehensive risk prediction. The tumour microenvironment, especially cancer‐associated fibroblasts (CAFs), plays a key role in DCIS progression. Fibroblast activation protein alpha (FAP), a CAF biomarker, has shown prognostic potential, but its clinical significance and spatial organization in DCIS remain rarely discussed. Methods: In this study, we employed a digital pathology pipeline to quantify stromal FAP expression and map its spatial organization. A total of 102 breast excision specimens were analysed, including pure DCIS and DCIS with co‐existing invasive carcinoma (either nearby or distant). FAP expression was quantified and correlated with clinicopathological features and survival outcomes. Results: Our results showed that FAP expression was significantly higher in DCIS with nearby invasion compared to DCIS with distant invasion ( P = 0.014) and pure DCIS ( P = 0.006), reaching levels comparable to the invasive component itself. Within these high‐FAP regions, no expression gradient from the invasive front was observed. In multivariable analysis, high FAP expression ( P = 0.053) and nuclear grade ( P = 0.043) were associated with invasion in older patients (≥50 years). Additionally, high FAP expression correlated with high nuclear grade ( P = 0.008), papillary DCIS ( P = 0.029) and HER2‐enriched subtype ( P = 0.0497). Although FAP was not an independent predictor of overall survival, it showed a trend towards poorer survival when combined with invasion. Conclusions: In conclusion, FAP is a promising biomarker for predicting nearby invasive carcinoma. Its integration into the existing risk stratification models could enhance clinically meaningful prediction.